CME TEST QUESTIONS: JULY 20

13

Examination available at http://learn.sirweb.org/. To take the online JVIR CME tests, please log into the SIRLearning Center with your SIR user name and password. Nonmembers: If you do not already have an SIR usernameand password, please click on “Create an Account” to gain access to the SIR Learning Center. Once in the LearningCenter, click on the “Publication” activity type for a listing of all available JVIR CME Tests. Each test will beavailable online for 3 years from the month/date of publication.

The CME questions in this issue are derived from the article “Survival Outcomes and Prognostic Factors ofTranscatheter Arterial Chemoembolization for Hepatic Neuroendocrine Metastases” by Hur et al.

1.

Neuroendocrine tumors (NETs) most commonlymetastasize to:a) The liverb) The spleenc) The axial skeletal systemd) The brain

2.

In this study, complete or partial response(RECIST) of hepatic metastasis from NETs follow-ing transcatheter arterial chemoembolization wasobserved in:a) o 10% of patientsb) 20%–30% of patientsc) 40%–70% of patientsd) 4 70% of patients

3.

In this study, the median overall survival for non-pancreatic NETs following chemoembolization wasin the range of:a) 3–6 weeksb) 6–12 monthsc) 3–5 yearsd) 5–10 years

4.

On a multivariate analysis, the authors concludedthat all of the following were significant prognosticfactors for overall survival following chemoemboli-zation EXCEPT:a) Total hepatic tumor burdenb) Total number of chemoembolizationsc) Presence of enterobiliary communicationd) Presence of extrahepatic metastasis

5.

Following chemoembolization, the presence of anenterobiliary communication puts the patient at asignificantly higher risk for:a) Postembolization syndromeb) Encephalopathyc) Variceal hemorrhaged) Liver abscess